Lena Friberg

Professor

Uppsala University

Sweden

Research Interests

Explore related searches

Professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Lena Friberg is affiliated with Uppsala Universitet in Sweden. Her research focuses on pharmacokinetics and pharmacodynamics, particularly in the context of antibiotics and biological therapies. Recent articles authored by Professor Friberg explore model-based approaches to drug development, exposure-tumor growth inhibition, and translational pharmacokinetic modeling related to various therapeutic agents.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Jon Ulf Hansen

Statens Serum Institut

DENMARK

View details

Mats Karlsson

Professor

Uppsala University

SWEDEN

View details

Sven N. Hobbie

University of Zurich

SWITZERLAND

View details

Vincent ARANZANA-CLIMENT

Associate Professor

University of Poitiers

FRANCE

View details

Elisabet I. Nielsen

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lena Friberg

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections

Plasma effects on bacterial time-kill dynamics: Insights from a PK/PD modelling analysis

Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study

Ceftazidime-avibactam (CAZ-AVI) pharmacokinetics in critically ill patients undergoing continuous venovenous hemodiafiltration (CVVHDF)

Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model

Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

A Model‐Based Approach to Evaluate Anti‐Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T‐Cell Bispecific Cibisatamab

Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery

A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidime

Simulation-based evaluation of the impact of dose fractionation study design on antibiotic PKPD analyses

Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models

A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer

Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the IMpower131 Study

Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies

Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors

Bayesian forecasting of tumor size metrics and overall survival

Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose

Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects

Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings

Collaborators (5)

Jon Ulf Hansen

Mats Karlsson

Sven N. Hobbie

Vincent ARANZANA-CLIMENT

Elisabet I. Nielsen

Make your next move.